Mandate

Vinge advises FSN Capital and Seriline in connection with the add-on acquisition of Areff Systems

Vinge advises FSN Capital and Seriline in connection with the acquisition of Areff Systems AB from its founders. The founders remain in the merged company and has reinvested a significant proportion of the purchase price in the group.

At the end of February 2022, the private equity firm FSN Capital acquired a majority stake in Seriline with the ambition of consolidating the market for physical and digital identity and access control. The acquisition of Seriline is now followed up with the acquisition of Areff Systems, where FSN Capital accounts for a majority of the financing. Areff Systems works with security and identification solutions and currently has 18 employees. The acquisition of Areff Systems will increase Seriline’s turnover with almost 50 percent to around SEK 150 million for 2022.

Vinge’s team mainly consisted of Johan Winnerblad, Maria Dahlin Kolvik, Eléonore Friberg and Ebba Nyberg (M&A), Mathilda Persson (IT), Sara Strandberg (Employment) and Axel Lennartsson (IPR).

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024